Skip to content
Triangle logo TriangleGet started
← Study library

NCT01078454 · REGISTRY CONDITION SEARCH

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2022-02-01

This randomized phase III trial is studying melphalan and dexamethasone to see how well they work with or without bortezomib in treating patients with previously untreated systemic amyloidosis. Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of plasma cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving melphalan together with dexamethasone is more effective with or without bortezomib in treating systemic amyloidosis.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR]) After 3 Months (3 Cycles) of Therapy

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically confirmed diagnosis of systemic light-chain amyloidosis * Histologic diagnosis of disease must be confirmed by pathology (positive Congo red stain with green birefringence on polarized light microscopy) * Genetic testing must be negative for transthyretin mutations associated with hereditary amyloidosis (required in patients who are African-American or who present with peripheral neuropathy as the dominant organ involvement) * Measurable disease, defined by \>= 1 of the following: * Serum M-protein \>= 1 g/dL by serum protein electrophoresis (SPEP) * Difference between involved and uninvolved free light chain be \>4.0mg/dL provided the kappa to lambda free light chain (FLC) ratio is abnormal * Symptomatic organ involvement\* (heart, kidney, liver/gastrointestinal tract, peripheral nervous system, or soft tissue), defined as any of the following: * NOTE: \*Carpal tunnel syndrome skin purpura or the presence of vascular amyloid on a bone marrow biopsy alone are not sufficient to meet criteria for "symptomatic organ involvement" * Renal involvement is defined as proteinuria (predominantly albumin) \> 0.5 g/day by 24-hour urine collection * Cardiac involvement is defined as the presence of a mean left ventricular wall thickness of \> 12 mm by echocardiogram in the absence of a history of hypertension or valvular heart disease or in the presence of unexplained low voltage (\< 0.5 mV) by electrocardiogram * Hepatic involvement is defined as hepatomegaly or an alkaline phosphatase \> 1.5 times upper limit of normal (ULN) * Peripheral nerve involvement is defined by clinical history or abnormal sensory and/or motor findings on neurologic exam * Gastrointestinal (GI) involvement is defined as gross GI bleeding or diarrhea (at least 4 stools per day over baseline); a positive GI biopsy is not sufficient to document clinical involvement * Autonomic nerve involvement is defined as orthostasis, symptoms of nausea or dysgeusia, gastric atony by gastric emptying scan, diarrhea, or constipation * Soft tissue and lymphatic involvement may be ascertained based on classic physical exam findings (macroglossia, shoulder pad sign, raccoon eyes, carpal tunnel syndrome, synovial enlargement, firm enlarged lymph nodes) or biopsy * Ineligible for autologous stem cell transplantation with melphalan 200 mg/m\^2 or refuses to undergo transplantation * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Amyloid cardiac biomarker stage I or II disease * The amyloid cardiac staging system is based on NT-proBNP and troponin-T levels. If troponin T (cTnT) is not available at local institution then troponin I (cTnI) may be used. Thresholds for cTnT, cTnI, and NT-proBNP are \< 0.035 ug/L, \< 0.1 ug/L, and \< 332 ng/L, respectively. Stage I patients have both troponin-T (or I) and NT-proBNP below the threshold. Stage II patients have either troponin-T (I) or NT-proBNP above the threshold. Stage III patients have troponin-T (or I) and simultaneous NT-proBNP above the threshold. Stage III patients are further classified as "better risk" if NT-proBNP is over 332 ng/L but less than 6000 ng/L * Negative pregnancy test * Fertile patients must use effective contraception * The absence of supine systolic blood pressure \< 100 mmHg and difficult to manage symptomatic orthostatic hypotension * Absolute neutrophil count (ANC) \> 1,500/mm\^3 * Platelet count \> 140,000/mm\^3 * Hemoglobin \> 10 g/dL * Total bilirubin \< 2.5 mg/dL * Alkaline phosphatase \< 5 times upper limit of normal (ULN) * Aspartate aminotransferase (AST) \< 3 times ULN * Creatinine clearance \> 30 mL/min * Bone marrow plasma cells \< 30% * Human immunodeficiency virus (HIV)-positivity allowed provided the following criteria are met: * No history of acquired immunodeficiency syndrome (AIDS)-defining events including history of CD4 cell count \< 200/mm\^3 * Current CD4 cell count \>= 350/mm\^3 * Not receiving zidovudine or stavudine * No secondary amyloidosis * More than 3 weeks since radiotherapy * Enrollment of subjects who require radiotherapy (which must be localized in field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy * More than 14 days since prior and no concurrent participation in clinical trials with other investigational agents not included in this trial Exclusion Criteria: * Pregnant or nursing * Clinically overt myeloma (hypercalcemia or lytic bone lesions) * Prior chemotherapy or radiotherapy for the treatment of myeloma or systemic light-chain amyloidosis * History of sustained ventricular tachycardias * Cardiac syncope * Uncompensated New York Heart Association (NYHA) class III or IV congestive heart failure * Uncontrolled infection * Active malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I cancer currently in complete remission * Serious medical or psychiatric illness likely to interfere with study participation, including recent myocardial infarction (within the past 6 months) or poorly controlled diabetes mellitus * Hypersensitivity to bortezomib, boron, or mannitol * Grade 2 or higher peripheral neuropathy
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: melphalan
    2. Drug: dexamethasone
    label
    ARM A (Mel-Dex)
    type
    EXPERIMENTAL
  2. description
    Patients receive melphalan 0.22 mg/kg PO and dexamethasone 40 mg PO on days 1-4 and bortezomib 1.3 mg/m\^2 intravenously (IV) on days 1, 4, 8, and 11 every 4 weeks. Treatment repeats every 4 weeks for 2 cycles. Patients then receive melphalan PO and dexamethasone PO on days 1-4 and bortezomib IV on days 1, 8, 15, and 22 every 5 weeks. Treatment repeats every 5 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: melphalan
    2. Drug: dexamethasone
    3. Drug: bortezomib
    label
    ARM B (B-Mel-Dex)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. ARM A (Mel-Dex)
    2. ARM B (B-Mel-Dex)
    description
    Given PO
    name
    melphalan
    other Names
    1. L-PAM
    2. L-phenylalanine mustard
    3. L-sarcolysin
    4. Alkeran
    5. NSC #8806
    type
    DRUG
  2. arm Group Labels
    1. ARM A (Mel-Dex)
    2. ARM B (B-Mel-Dex)
    description
    Given PO
    name
    dexamethasone
    other Names
    1. Decadron
    2. Hexadrol
    3. Dexameth
    4. Dexone
    5. DXM
    type
    DRUG
  3. arm Group Labels
    1. ARM B (B-Mel-Dex)
    description
    Given IV
    name
    bortezomib
    other Names
    1. Velcade®
    2. PS-341
    3. MLN-341
    4. LDP-341
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
11
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    sCR: ACR and no clonal cells in bone marrow (BM) ACR: Negative serum/urine immunofixation (IF), \<5% plasma cells in BM, and normal serum FLC ratio VGPR: 1. PR and any of the following; 2. serum/urine M-protein detectable by IF but not measurable (NM) on electrophoresis (EP); (3) ≥90% reduction in serum M-component and urine M-protein \<100 mg/24 hr if baseline serum measurable; (4) urine M-component \<100 mg/24 hr and NM serum M-protein on serum protein EP if baseline urine measurable; (5) ≥90% drop in the difference between involved and uninvolved FLC levels if only FLC measurable PR: (1) ≥50% drop of serum M-protein and 24-hr urinary M-protein drop by ≥90% or to \<200 mg/24 hr if baseline serum/urine measurable; or (2) ≥50% drop of serum M-protein if only serum measurable at baseline; or (3) 24-hr urinary M-protein drop by ≥90% or to \<200 mg/24 hr if baseline urine measurable; or (4) ≥ 50% drop in the difference between involved and uninvolved FLC if only FLC measu
    measure
    Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR]) After 3 Months (3 Cycles) of Therapy
    time Frame
    Assessed at 3 months
Full study description
brief Summary
This randomized phase III trial is studying melphalan and dexamethasone to see how well they work with or without bortezomib in treating patients with previously untreated systemic amyloidosis. Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of plasma cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving melphalan together with dexamethasone is more effective with or without bortezomib in treating systemic amyloidosis.
detailed Description
PRIMARY OBJECTIVES: I. To compare hematologic overall response (partial response \[PR\], very good PR, amyloid complete hematologic response \[ACR\], and stringent complete response \[sCR\]) after 3 courses of therapy in patients with previously untreated systemic light-chain amyloidosis treated with melphalan and dexamethasone with vs without bortezomib. SECONDARY OBJECTIVES: I. To evaluate the ACR rate after 3 courses of therapy and at completion of therapy. II. To evaluate organ response rates after 3 courses of therapy and at 6, 9, and 12 months. III. To evaluate treatment-related mortality. IV. To evaluate toxicity. V. To evaluate progression-free and overall survival. VI. To evaluate PR or better at completion of therapy. VII. To evaluate time to hematologic and organ response. VIII. To evaluate the duration of hematologic and organ response. IX. To assess quality of life (QOL) at baseline, at 3, 6, and 9 months during the therapy, at completion of therapy, and 3 and 6 months after therapy. TERTIARY OBJECTIVES: I. To determine the prognostic impact of t(11;14) translocation and cyclin D1 overexpression on response and overall survival. II. (Correlative) To compare sCR rates and to determine the impact of sCR on the outcomes. III. (Correlative) To perform a descriptive analysis of amyloid typing and proteomic composition of amyloid tissues. OUTLINE: This is a multicenter study. Patients are stratified according to amyloid cardiac stage (stage I/II vs. better risk stage III) and are randomized to 1 of 2 treatment arms. ARM A (Mel-Dex): Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity. ARM B (B-Mel-Dex): Patients receive melphalan 0.22 mg/kg PO and dexamethasone 40 mg PO on days 1-4 and bortezomib 1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 every 4 weeks. Treatment repeats every 4 weeks for 2 cycles. Patients then receive melphalan PO and dexamethasone PO on days 1-4 and bortezomib IV on days 1, 8, 15, and 22 every 5 weeks. Treatment repeats every 5 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Blood, urine, bone marrow, and fat samples may be collected periodically for laboratory analysis. Health-related quality of life is assessed periodically before, during, and after therapy. After completion of study treatment, patients are followed up periodically for 5 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5b36d67e4341dd77e294
      requested nct id
      NCT01078454
      primary nct id
      NCT01078454
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      d1091cb14b6556249012a5904812821fab8edf184ea0ac0851934fc1c4423216
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5b36d67e4341dd77e294
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01078454
      occurrences
      1. context exact
        NCT01078454
        end
        11
        exact text
        NCT01078454
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/412/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      256fafc53451b8e738e43233567ecd77c3a804bc2a78757c709c290c7ade58d3

    Preserved source evidence · Not medical advice